FierceBiotech 15 avr. 2026 Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
FierceBiotech 27 mars 2026 Novartis pens $2B deal for allergy biotech with potential Xolair successor
Endpoints News 27 mars 2026 Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate
Endpoints News 25 mars 2026 Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis' Scemblix
Endpoints News 23 mars 2026 Novartis to invest $480M in China following AstraZeneca and Lilly pledges
FierceBiotech 23 mars 2026 Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D
FierceBiotech 20 mars 2026 Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle
Endpoints News 20 mars 2026 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News 16 mars 2026 After Novartis pact, macrocycle shop Unnatural Products gets $45M Series B
FierceBiotech 27 févr. 2026 Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates